Catheter Precision Sees Prelim Q2 Revenue $94.84K Vs $288K Est.
$VTAK
Medical/Dental Instruments
Health Care
Catheter Precision Sees Prelim Q2 Revenue $94.84K Vs $288K Est.
Save time and jump to the most important pieces.
FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the New York City area.As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the NYC region.The most recent purchase order comes from Montefiore Medical Center located in the Bronx, NY. Montefiore is a premiere academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in New York City. MMC is a part
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i
FORT MILL, SC / ACCESSWIRE / November 4, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company, today announced that new clinical data from the VIVO EU Registry was presented last week at the Society of Cardiac Robotic Navigation (SCRN) meeting in Lisbon, Portugal.As previously announced, there were three presentations about VIVO during the SCRN meeting which took place October 28-29. The presentation by Professor Leonor Parreira shared the final data from Hospital da Luz. This center enrolled 27 subjects of which 18 proceeded with an ablation procedure with the following results:100% accurate identification of the site of origin to the exact or neighbor
FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)
SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i
FORT MILL, SC / ACCESSWIRE / December 22, 2023 / Catheter Precision, Inc. (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the third quarter of 2023.Highlights of the third quarter include the following: Received approval for first purchase in France. VIVO is now active in six European countries. Completed enrollment of Phase I LockeT study in excess of 100 patients. Received Institutional Review Board (IRB) approval for Phase II LockeT study and began enrolling patients. This study is a one-to-one randomized study comparing outcomes of standard of care to LockeT. Finalized n
FORT MILL, SC / ACCESSWIRE / December 18, 2023 / Catheter Precision, Inc. (formerly known as Ra Medical Systems, Inc.) (NYSE:VTAK) an innovative US-based medical device Company dedicated to improving the lives of patients with cardiac arrhythmias, announced corporate highlights of the second quarter of 2023.Highlights of the second quarter include the following:US sales team was assembled, trained, and is creating a pipeline.Additional US clinical personnel were onboarded and trained.Completion of enrollment of 125 patient VIVO patient Registry. Follow-up data is expected to be completed in June 2024.Key VIVO accounts continue to be established in both the US and Europe.Initiation of first L
3 - Catheter Precision, Inc. (0001716621) (Issuer)
3 - Catheter Precision, Inc. (0001716621) (Issuer)
4 - Catheter Precision, Inc. (0001716621) (Issuer)
Catheter Precision, Inc. (NYSE:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.As previously disclosed, the EU registry enrolled 125 patients with an aim to gather real world data about the use and benefits of VIVO, outside of a rigorous clinical study. The data serves multiple purposes including fulfilling European regulatory requirements for on-going data collection, publication of multi-center data, and future development of studies and improvements to the VIVO technology, including a demonstration of the ac
U.S. stocks traded higher toward the end of trading, with the Dow Jones index rising more than 150 points on Monday. The Dow traded up 0.44% to 40,178.06 while the NASDAQ rose 0.29% to 18,451.73. The S&P 500 also rose, gaining, 0.25% to 5,629.59. Check This Out: Over $18M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying Leading and Lagging SectorsEnergy shares jumped by 2% on Monday. In trading on Monday, utilities shares fell by 1.8%. Top Headline Goldman Sachs Group Inc. (NYSE:GS) reported better-than-expected results for its second quarter. Goldman posted revenue of $12.730 billion for the second quarter, beating the consensus of $12.456 billion.
S-1 - Catheter Precision, Inc. (0001716621) (Filer)
PRE 14A - Catheter Precision, Inc. (0001716621) (Filer)
8-K - Catheter Precision, Inc. (0001716621) (Filer)